Prescription Attached:-

đŠē LIPU MED â COMPLETE CLINICAL PRESCRIPTION REVIEW
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ: āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻāϰā§āĻļāύā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āϤāϞāĻĒā§āĻā§ āĻŦā§āϝāĻĨāĻž āĻ āĻ āϞā§āĻĒ āϝā§āύāĻŋāĻĒāĻĨā§ āϰāĻā§āϤāĻĒāĻžāϤ; āϏāĻā§āĻā§ āϏāĻžāĻŦāĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻšāĻžāĻāĻĒā§āĻĨāĻžāĻāϰāϝāĻŧā§āĻĄāĻŋāĻāĻŽā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒā§āϰā§āĻŦāĻāϤāĻŋāĻšāĻžāϏāĨ¤
Website-verified case numbering: raiyyantahsan.com-āĻāϰ Medical Blog āĻāĻŦāĻ Gynecology archive āϝāĻžāĻāĻžāĻ āĻāϰ⧠āϏāϰā§āĻŦāĻļā§āώ āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ Total Case TC(1372), Department Code 09 āĻāĻŦāĻ Gynecology Case No 46 āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āĻā§āĨ¤ āϏā§āĻ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻ āύāϤā§āύ āĻŦā§āϞāĻā§āϰ āĻĒāϰāĻŦāϰā§āϤ⧠āύāĻŽā§āĻŦāϰ TC(1373).(09).Gynecology Department Case No (47)āĨ¤
Prescription reviewed: One handwritten prescription from AMZ Hospital Ltd.
Prescribing consultant: Professor Dr. Jesmine Banu
Specialty: Obstetrics and Gynaecology
Patient: Lipi â āĻāĻŦāĻŋāϤ⧠āĻāĻ āύāĻžāĻŽāĻāĻŋ āĻĻā§āĻāĻž āϝāĻžāĻā§āĻā§āĨ¤
Age: Approximately 39 years
Prescription date: 08 March 2025, as written on the prescription
Review date: Friday, 16 October 2026
Overall clinical interpretation confidence: 0.84/1.00
Important: āĻāĻ āĻĒā§āϰāϤāĻŋāĻŦā§āĻĻāύāĻāĻŋ āĻĒā§āϰā§āύ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ retrospective clinical reviewāĨ¤ āϰā§āĻā§āϰ āĻŦāϰā§āϤāĻŽāĻžāύ āĻ āĻŦāϏā§āĻĨāĻž āύāĻž āĻĻā§āĻā§ āĻāĻ āĻāώā§āϧāĻā§āϞ⧠āύāϤā§āύ āĻāϰ⧠āĻļā§āϰ⧠āĻāϰāĻž āĻŦāĻž āĻāĻā§āϰ antibiotic regimen āĻĒā§āύāϰāĻžāĻŦā§āϤā§āϤāĻŋ āĻāϰāĻž āĻāĻāĻŋāϤ āύāϝāĻŧāĨ¤
1. Prescription Overview â āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻžāϰāϏāĻāĻā§āώā§āĻĒ
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āĻāĻāĻāύ gynecological postoperative follow-up āϰā§āĻā§āĻā§ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰā§āĻā§āύāĨ¤
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻŽā§āϞ clinical issues:
1. Seven days following a gynecological procedure: āϏā§āϤā§āϰā§-āϰā§āĻāϏāĻāĻā§āϰāĻžāύā§āϤ āĻāĻāĻāĻŋ āĻĒā§āϰāĻā§āϰāĻŋāϝāĻŧāĻžāϰ āϏāĻžāϤ āĻĻāĻŋāύ āĻĒāϰ āĻĢāϞā§āĻāĻĒāĨ¤
2. History of cervical erosion: āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻāϰā§āĻļāύā§āϰ āĻĒā§āϰā§āĻŦāĻāϤāĻŋāĻšāĻžāϏāĨ¤
3. Lower abdominal/pelvic pain: āϤāϞāĻĒā§āĻ āĻŦāĻž āĻļā§āϰā§āĻŖāĻŋ āĻ āĻā§āĻāϞ⧠āĻŦā§āϝāĻĨāĻžāĨ¤
4. Mild vaginal bleeding: āϝā§āύāĻŋāĻĒāĻĨā§ āĻ āϞā§āĻĒ āϰāĻā§āϤāĻĒāĻžāϤāĨ¤
5. Possible subclinical hypothyroidism: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻžāĻŦāĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻšāĻžāĻāĻĒā§āĻĨāĻžāĻāϰāϝāĻŧā§āĻĄāĻŋāĻāĻŽāĨ¤
Confidence: 0.86
Corrected Medicine Identification
āĻāĻĒāύāĻžāϰ āϏāĻāĻļā§āϧāύ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāϝāĻŧāĻāĻŋ āĻāώā§āϧā§āϰ āϏāĻ āĻŋāĻ āύāĻžāĻŽ āĻ generic āĻāĻāύ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
| No. | Correct Brand Name | Generic Name | Strength | Manufacturer |
|---|---|---|---|---|
| 1 | Fluclox | Flucloxacillin Sodium | 500 mg capsule | ACI |
| 2 | Ornil | Ornidazole | 500 mg tablet | Opsonin Pharma |
| 3 | Algin | Tiemonium Methylsulfate | 50 mg tablet | Renata |
| 4 | Esonix | Esomeprazole | 20 mg tablet | Incepta |
| 5 | Thyrox | Levothyroxine Sodium | 50 mcg tablet | Renata |
| 6 | Folix | Folinic Acid | 5 mg tablet | ACME |
Medicine identification confidence: 1.00 for user-confirmed medicines 1, 2 and 6; approximately 0.95 for the other three medicines.
āϏāĻŦāĻā§āϝāĻŧā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏāĻāĻļā§āϧāύ āĻšāϞ⧠Folix 5 mg-āĻāϰ generic Folinic Acid, Folic Acid āύāϝāĻŧāĨ¤ MedEx-āĻ āĻāϝāĻŧāĻāĻŋ āĻāώā§āϧā§āϰ generic āĻ brand information āĻŽāĻŋāϞāĻŋāϝāĻŧā§ āĻĻā§āĻāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
2. Definition â āϰā§āĻā§āϰ āϏāĻāĻā§āĻāĻž
Cervical Erosion / Cervical Ectropion
Definition: Cervical ectropion is a benign condition in which endocervical columnar epithelium becomes visible on the outer surface of the cervix.
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻā§āϤāϰā§āϰ āύāϰāĻŽ glandular cells āĻŦāĻžāĻāϰā§āϰ āĻ āĻāĻļā§ āĻĻā§āĻāĻž āϝāĻžāĻāϝāĻŧāĻžāĻā§ cervical ectropion āĻŦāϞāĻž āĻšāϝāĻŧāĨ¤ āĻāĻā§ āĻāĻ āĻ āĻŦāϏā§āĻĨāĻžāĻā§ āĻĒā§āϰāĻžāϝāĻŧāĻ cervical erosion āĻŦāϞāĻž āĻšāϤā§āĨ¤
āĻāϤ⧠āĻāĻāύ⧠vaginal discharge, contact bleeding āĻ āĻĨāĻŦāĻž intercourse-āĻāϰ āĻĒāϰ⧠spotting āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ cervical ectropion āύāĻŋāĻā§ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻā§āϝāĻžāύāϏāĻžāϰ āύāϝāĻŧāĨ¤
Confidence: 0.98
Postprocedural Pelvic Pain
Definition: Pelvic discomfort occurring after gynecological instrumentation or treatment.
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻ āĻŦāĻž āĻāϰāĻžāϝāĻŧā§āϰ āĻā§āύ⧠āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāĻĻā§āϧāϤāĻŋāϰ āĻĒāϰ⧠āϤāϞāĻĒā§āĻā§ āĻŦā§āϝāĻĨāĻž āĻšāĻāϝāĻŧāĻžāĨ¤
āĻāϰ āĻāĻžāϰāĻŖ āĻšāϤ⧠āĻĒāĻžāϰ⧠āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ healing, uterine cramping, local inflammation āĻ āĻĨāĻŦāĻž āĻā§āύ⧠postoperative complicationāĨ¤
Subclinical Hypothyroidism
Definition: Serum TSH above the reference range with normal FT4.
āĻŦāĻžāĻāϞāĻž: āϰāĻā§āϤ⧠TSH āĻŦā§āĻĄāĻŧā§ āĻā§āϞā§āĻ FT4 āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĨāĻžāĻāĻžāĻā§ āϏāĻžāĻŦāĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻšāĻžāĻāĻĒā§āĻĨāĻžāĻāϰāϝāĻŧā§āĻĄāĻŋāĻāĻŽ āĻŦāϞāĻž āĻšāϝāĻŧāĨ¤
Confidence: 0.99
3. Chief Complaints (C/C) â āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
| Doctor's Writing | English Interpretation | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Confidence |
|---|---|---|---|
| 7 POD following D&C & EC â probable | Seven days after a gynecological procedure | āϏā§āϤā§āϰā§-āϰā§āĻāϏāĻāĻā§āϰāĻžāύā§āϤ āĻĒā§āϰāĻā§āϰāĻŋāϝāĻŧāĻžāϰ āϏāĻžāϤ āĻĻāĻŋāύ āĻĒāϰ | 0.78 |
| Pelv. abd. pain | Pelvic/lower abdominal pain | āϤāϞāĻĒā§āĻā§ āĻŦā§āϝāĻĨāĻž | 0.94 |
| F/U | Follow-up | āĻĢāϞā§āĻāĻĒā§ āĻāϏā§āĻā§āύ | 0.97 |
| V/B â 2 days (mild) | Mild vaginal bleeding for two days | āĻĻā§āĻ āĻĻāĻŋāύ āϧāϰ⧠āĻ āϞā§āĻĒ āϝā§āύāĻŋāĻĒāĻĨā§ āϰāĻā§āϤāĻĒāĻžāϤ | 0.90 |
Clinical significance
Postoperative pain and mild bleeding āĻ āύā§āĻ āĻā§āώā§āϤā§āϰ⧠āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ recovery-āϰ āĻ āĻāĻļ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ āĻŦā§āϝāĻĨāĻž āĻŦā§āĻĄāĻŧā§ āϝāĻžāĻāϝāĻŧāĻž, āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āϰāĻā§āϤāĻĒāĻžāϤ, āĻā§āĻŦāϰ āĻŦāĻž āĻĻā§āϰā§āĻāύā§āϧāϝā§āĻā§āϤ āϏā§āϰāĻžāĻŦ āĻĨāĻžāĻāϞ⧠postoperative infection āĻŦāĻž āĻ āύā§āϝ complication āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāϝāĻŧāĨ¤
Confidence: 0.96
4. Menstrual History (M/H) â āĻŽāĻžāϏāĻŋāĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ
| History | English | āĻŦāĻžāĻāϞāĻž | Confidence |
|---|---|---|---|
| MP: 7/3/25 â probable | Menstrual period date | āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŽāĻžāϏāĻŋāĻā§āϰ āϤāĻžāϰāĻŋāĻ ā§ āĻŽāĻžāϰā§āĻ ā§¨ā§Ļ⧍ā§Ģ | 0.70 |
| MC: R/4â5 days | Regular menstruation, duration 4â5 days | āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āĻŽāĻžāϏāĻŋāĻ, āϏāĻžāϧāĻžāϰāĻŖāϤ ā§Ēâā§Ģ āĻĻāĻŋāύ | 0.90 |
| F: Avg | Average menstrual flow | āĻŽāĻžāĻāĻžāϰāĻŋ āϰāĻā§āϤāĻĒāĻžāϤ | 0.95 |
| S: âve | Negative symptom marker, exact meaning unclear | āĻāĻāĻāĻŋ āĻāĻĒāϏāϰā§āĻ āĻ āύā§āĻĒāϏā§āĻĨāĻŋāϤ; āϏāĻāĻā§āώāĻŋāĻĒā§āϤ āϰā§āĻĒ āĻ āϏā§āĻĒāώā§āĻ | 0.50 |
Clinical note: āĻŽāĻžāϏāĻŋāĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨā§āĻā§ āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ menstrual disorder āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤
5. Obstetric History (O/H) â āĻĒā§āϰāϏā§āϤāĻŋ āĻāϤāĻŋāĻšāĻžāϏ
| Prescription Note | Interpretation | āĻŦāĻžāĻāϞāĻž |
|---|---|---|
| 3 NVD | Three normal vaginal deliveries | āϤāĻŋāύāĻŦāĻžāϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĒā§āϰāϏāĻŦ |
| +0 | Possibly no abortion history | āϏāĻŽā§āĻāĻŦāϤ āĻāϰā§āĻāĻĒāĻžāϤā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āύā§āĻ; āύāĻŋāĻļā§āĻāĻŋāϤāĻāϰāĻŖ āĻĒā§āϰāϝāĻŧā§āĻāύ |
| F: 22 yrs | First childbirth-related entry, interpretation uncertain | āĻĒā§āϰāĻĨāĻŽ āϏāύā§āϤāĻžāύāϏāĻāĻā§āϰāĻžāύā§āϤ ⧍⧍ āĻŦāĻāϰā§āϰ āĻāĻāĻāĻŋ āϤāĻĨā§āϝ |
| LC: 12 yrs | Last child approximately 12 years | āϏāϰā§āĻŦāĻļā§āώ āϏāύā§āϤāĻžāύā§āϰ āĻŦāϝāĻŧāϏ āϏāĻŽā§āĻāĻŦāϤ ⧧⧍ āĻŦāĻāϰ |
Provisional obstetric history: G3P3 āĻšāϤ⧠āĻĒāĻžāϰā§, āĻāĻŋāύā§āϤ⧠āĻĒā§āϰā§āĻŖ gravidity āĻ abortion history āύāĻŋāĻļā§āĻāĻŋāϤ āύāϝāĻŧāĨ¤
Confidence: 0.85
Drug History (D/H)
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠Thyrox 50 mcg āϰāϝāĻŧā§āĻā§āĨ¤ āĻāĻāĻŋ āĻāĻā§ āĻĨā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāĻā§āĻāĻŋāϞ, āύāĻžāĻāĻŋ āύāϤā§āύ āĻāϰ⧠āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§âāϏā§āĻāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āύāϝāĻŧāĨ¤
Allergy history: Not documented.
6. Physical Examination, Doctor's Dx, Investigations and Advice
O/S/E â On Systemic Examination
| Parameter | Prescription Finding | āĻŦāĻžāĻāϞāĻž |
|---|---|---|
| Blood pressure | Approximately 100/80 mmHg | āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰāĻā§āϤāĻāĻžāĻĒ ā§§ā§Ļā§Ļ/ā§Žā§Ļ |
| Body weight | Approximately 84 kg | āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻāύ ā§Žā§Ē āĻā§āĻāĻŋ |
| Pulse | Not documented clearly | āϏā§āĻĒāώā§āĻ āϞā§āĻāĻž āύā§āĻ |
| Temperature | Not documented | āϞā§āĻāĻž āύā§āĻ |
| BMI | Cannot determine | āĻāĻā§āĻāϤāĻž āύāĻž āĻĨāĻžāĻāĻžāϝāĻŧ āĻšāĻŋāϏāĻžāĻŦ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻž |
Confidence: 0.88 for visible findings.
O/E â General Examination
Pallor, edema, abdominal tenderness āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ general examination findings āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āύāĻĨāĻŋāĻā§āĻā§āϤ āύā§āĻāĨ¤
O/G/E â Obstetric and Gynecological Examination
Speculum examination, cervical appearance, uterine tenderness, cervical motion tenderness āĻ āĻĨāĻŦāĻž adnexal findings āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
Clinical significance: āĻāϏāĻŦ āϤāĻĨā§āϝ āĻāĻžāĻĄāĻŧāĻž postoperative infection āύāĻŋāĻļā§āĻāĻŋāϤ āĻŦāĻž āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻŦāĻžāĻĻ āĻĻā§āĻāϝāĻŧāĻž āϏāĻŽā§āĻāĻŦ āύāϝāĻŧāĨ¤
Doctor's Diagnosis (Dx)
āĻāĻĒāϰā§āϰ handwritten note āĻĨā§āĻā§ āύāĻŋāĻŽā§āύāϞāĻŋāĻāĻŋāϤ āĻŦāĻŋāώāϝāĻŧāĻā§āϞ⧠āĻŦā§āĻāĻž āϝāĻžāϝāĻŧ:
1. Seven days postoperative following a gynecological procedure.
āĻŦāĻžāĻāϞāĻž: āϏā§āϤā§āϰā§-āϰā§āĻāϏāĻāĻā§āϰāĻžāύā§āϤ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāĻĻā§āϧāϤāĻŋāϰ āϏāĻžāϤ āĻĻāĻŋāύ āĻĒāϰāĻŦāϰā§āϤ⧠āĻ āĻŦāϏā§āĻĨāĻžāĨ¤
2. History of cervical erosion.
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻāϰā§āĻļāύā§āϰ āĻĒā§āϰā§āĻŦāĻāϤāĻŋāĻšāĻžāϏāĨ¤
3. Possible SCH â Subclinical Hypothyroidism.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻžāĻŦāĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻšāĻžāĻāĻĒā§āĻĨāĻžāĻāϰāϝāĻŧā§āĻĄāĻŋāĻāĻŽāĨ¤
4. Previous history of three normal vaginal deliveries.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āĻŦā§ āϤāĻŋāύāĻŦāĻžāϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĒā§āϰāϏāĻŦ āĻšāϝāĻŧā§āĻā§āĨ¤
Doctor's Dx transcription confidence: 0.80
Investigations Prescribed
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāϤā§āύ āĻāϰ⧠āĻā§āύ⧠investigation āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āϞā§āĻāĻž āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
Documented investigations: None clearly identifiable.
Doctor's Advice
âHPV vaccine â 3 doses complete.â
āĻŦāĻžāĻāϞāĻž: HPV vaccine-āĻāϰ āϤāĻŋāύ āĻĄā§āĻ āϏāĻŽā§āĻĒāύā§āύ āĻšāϝāĻŧā§āĻā§āĨ¤
āĻāĻāĻŋ vaccination history āĻšāĻŋāϏā§āĻŦā§ āϞā§āĻāĻž āĻšāϝāĻŧā§āĻā§ āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§; āύāϤā§āύ āϤāĻŋāύ āĻĄā§āĻ āύā§āĻāϝāĻŧāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļ āύāϝāĻŧāĨ¤
Confidence: 0.95
đŠ 7. Prescribed Drug Analysis â MedEx āĻ āύā§āϝāĻžāϝāĻŧā§
7.1 Original Prescription: Corrected Medicine Audit
| No. | Original Medicine | Prescription Dose â Apparent | Drug Category | Main Purpose |
|---|---|---|---|---|
| 1 | Cap. Fluclox 500 mg | 1+1+1; duration unclear | Penicillin antibiotic | Suspected susceptible bacterial infection |
| 2 | Tab. Ornil 500 mg | 1+1+1; approximately 5 days | Nitroimidazole antimicrobial | Possible anaerobic/protozoal infection |
| 3 | Tab. Algin 50 mg | 1+1+1 | Antispasmodic | Pelvic spasm/pain |
| 4 | Tab. Esonix 20 mg | 1+0+1 | PPI | Gastric acid suppression |
| 5 | Tab. Thyrox 50 mcg | 1+0+0 | Thyroid hormone | Hypothyroidism management |
| 6 | Tab. Folix 5 mg | 0+1+0 | Folinic acid preparation | Folate-related indication, not established |
Important prescription safety finding: Fluclox āĻāĻŦāĻ Ornil-āĻāϰ āĻšāĻžāϤ⧠āϞā§āĻāĻž frequency 1+1+1 āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§āĨ¤ āĻāĻŋāύā§āϤ⧠āĻāĻ dosing pattern āϰā§āĻ, āĻā§āĻŦāĻžāĻŖā§ āĻ treatment indication āĻ āύā§āϝāĻžāϝāĻŧā§ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻāϰā§āϰāĻŋāĨ¤ āύāĻŋāĻā§ MedEx-āĻāϰ standard doses-āĻāϰ āϏāĻā§āĻā§ āϤā§āϞāύāĻž āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤ āĻāĻāĻŋ āĻāĻā§āϰ prescription āĻ āύā§āϏāϰāĻŖ āĻāϰāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļ āύāϝāĻŧāĨ¤
Medicine 1 â Cap. Fluclox 500 mg
1. Generic Name
Flucloxacillin Sodium â āĻĢā§āϞā§āĻā§āϞāĻā§āϏāĻžāϏāĻŋāϞāĻŋāύ āϏā§āĻĄāĻŋāϝāĻŧāĻžāĻŽāĨ¤
2. Brand Name
Fluclox 500 mg Capsule
Manufacturer: Advanced Chemical Industries PLC (ACI).
3. MedEx Alternative Brands
A-Flox, Adflox, Ancoc āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ Flucloxacillin brandsāĨ¤
4. MedEx Therapeutic Class
Narrow Spectrum Penicillin.
5. Pharmacological Class
Beta-lactam antibiotic; penicillinase-resistant isoxazolyl penicillin.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āύāĻŋāϏāĻŋāϞāĻŋāύ-āĻāĻžāϤā§āϝāĻŧ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋāϝāĻŧāĻžāύāĻžāĻļāĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžāϝāĻŧā§āĻāĻŋāĻāĨ¤
6. Use/Purpose of Drug
Gram-positive bacterial infections, āĻŦāĻŋāĻļā§āώ āĻāϰ⧠susceptible staphylococcal infection-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
7. Why Doctor Prescribed This Drug in This Patient
Possible reason: Gynecological procedure-āĻāϰ āĻĒāϰ⧠susceptible bacterial infection āĻĒā§āϰāϤāĻŋāϰā§āϧ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋāϝāĻŧāĻžāϰ āϏāĻāĻā§āϰāĻŽāĻŖ āĻĨāĻžāĻāϞ⧠āĻ āĻĨāĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŦāĻŋāĻŦā§āĻāύāĻžāϝāĻŧ āϤāĻžāϰ āĻā§āĻāĻāĻŋ āĻĨāĻžāĻāϞ⧠āĻāĻ antibiotic āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ āĻļā§āϧ⧠postoperative āĻ āĻŦāϏā§āĻĨāĻž āĻĨā§āĻā§ antibiotic indication āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤
Patient-specific rationale confidence: 0.65
8. Side Effects
Nausea, vomiting, diarrhea, skin rash, urticaria āĻāĻŦāĻ rare cholestatic hepatitisāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻŦāĻŽāĻŋāĻāĻžāĻŦ, āĻĄāĻžāϝāĻŧāϰāĻŋāϝāĻŧāĻž, āϤā§āĻŦāĻā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻ āĻŦāĻŋāϰāϞ āĻā§āώā§āϤā§āϰ⧠āϝāĻā§āϤā§āϰ āĻā§āώāϤāĻŋāĨ¤
9. MedEx Link
10. Unit Price, Strip Price and Other Composition
Unit price: ā§ŗ14.00
Strip price: ā§ŗ140.00 (10 capsules)
Other formulations include 250 mg capsule, 125 mg/5 mL and 250 mg/5 mL oral suspension, and injectable preparations.
11. Mechanism of Action
Flucloxacillin inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins and interfering with peptidoglycan cross-linking.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋāϝāĻŧāĻžāϰ cell wall āϤā§āϰāĻŋ āĻŦāύā§āϧ āĻāϰ⧠āĻā§āĻŦāĻžāĻŖā§ āϧā§āĻŦāĻāϏ āĻāϰā§āĨ¤
12. Drug Indications
Skin and soft-tissue infections, infected wounds, cellulitis, abscesses, susceptible respiratory infections, osteomyelitis āĻāĻŦāĻ selected other infections caused by susceptible organismsāĨ¤
13. Drug Interactions and Contraindications
Contraindication: Penicillin hypersensitivityāĨ¤
Interactions: Probenecid flucloxacillin level āĻŦāĻžāĻĄāĻŧāĻžāϤ⧠āĻĒāĻžāϰā§; methotrexate-āĻāϰ clearance āĻĒā§āϰāĻāĻžāĻŦāĻŋāϤ āĻšāĻāϝāĻŧāĻžāϰ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
14. Precautions and Warnings
Previous penicillin allergy, hepatic dysfunction āĻāĻŦāĻ renal impairment āĻĨāĻžāĻāϞ⧠āϏāϤāϰā§āĻāϤāĻž āĻāϰā§āϰāĻŋāĨ¤
15. Dosage and Administration
MedEx-āĻ āϏāĻžāϧāĻžāϰāĻŖ adult oral dose āĻšāĻŋāϏā§āĻŦā§ 250 mg four times daily āĻāϞā§āϞā§āĻ āĻāĻā§; infection severity āĻ āύā§āϝāĻžāϝāĻŧā§ dose adjustment āĻāϰāĻž āĻšāϝāĻŧāĨ¤ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻāĻžāĻŦāĻžāϰā§āϰ āĻāĻ āĻāĻŖā§āĻāĻž āĻāĻā§ āύā§āĻāϝāĻŧāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļ āϰāϝāĻŧā§āĻā§āĨ¤
Prescription shows: āϏāĻŽā§āĻāĻŦāϤ 500 mg āϤāĻŋāύāĻŦāĻžāϰ āĻĻā§āύāĻŋāĻāĨ¤ āĻāĻāĻŋ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϏāĻāĻā§āϰāĻŽāĻŖ āĻ indication āĻ āύā§āϝāĻžāϝāĻŧā§ prescriber-āĻāϰ āϏāĻā§āĻā§ āϝāĻžāĻāĻžāĻāϝā§āĻā§āϝāĨ¤
16. Pregnancy and Lactation
Pregnancy-āϤ⧠āϏā§āĻĒāώā§āĻ indication āĻĨāĻžāĻāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ benefitârisk assessment āĻ āύā§āϝāĻžāϝāĻŧā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤ Breast milk-āĻ āĻ āϞā§āĻĒ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āϝā§āϤ⧠āĻĒāĻžāϰā§; nursing infant-āĻ diarrhea, thrush āĻŦāĻž allergy āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Clinical confidence: 0.98 for verified pharmacology; 0.65 for patient-specific indication.
Medicine 2 â Tab. Ornil 500 mg
1. Generic Name
Ornidazole â āĻ āϰā§āύāĻŋāĻĄāĻžāĻāϞāĨ¤
2. Brand Name
Ornil 500 mg Tablet
Manufacturer: Opsonin Pharma Ltd.
3. MedEx Alternative Brands
Ornid, Ornizol, Robic, Troniz āĻāĻŦāĻ XynorāĨ¤
4. MedEx Therapeutic Class
Amoebicides, Anti-diarrhoeal Antiprotozoal.
5. Pharmacological Class
5-Nitroimidazole antimicrobial â Antiprotozoal and anti-anaerobic agent.
6. Use/Purpose of Drug
Anaerobic bacterial infection āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ protozoal infection-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
7. Why Doctor Prescribed This Drug in This Patient
Possible reason: Postprocedural anaerobic infection coverage āĻ āĻĨāĻŦāĻž vaginal infection-āĻāϰ āϏāύā§āĻĻā§āĻšā§ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĒāϰ⧠āĻāĻŋāĻā§ anaerobic āĻā§āĻŦāĻžāĻŖā§āϰ āĻŦāĻŋāϰā§āĻĻā§āϧ⧠āĻāĻŋāĻāĻŋā§āϏāĻž āĻĻā§āĻāϝāĻŧāĻžāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ āϰā§āĻā§āϰ bacterial vaginosis, trichomoniasis āĻŦāĻž pelvic infection āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāĻāϝāĻŧāĻžāϰ āĻā§āύ⧠test āĻŦāĻž examination finding āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
Patient-specific rationale confidence: 0.65
8. Side Effects
Nausea, vomiting, abdominal pain, dizziness, headache, drowsiness āĻāĻŦāĻ rare leukopeniaāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻŦāĻŽāĻŋāĻāĻžāĻŦ, āĻĒā§āĻāĻŦā§āϝāĻĨāĻž, āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž, āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ āĻŦāĻŋāϰāϞ āĻā§āώā§āϤā§āϰ⧠āĻļā§āĻŦā§āϤ āϰāĻā§āϤāĻāĻŖāĻŋāĻāĻž āĻāĻŽā§ āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
9. MedEx Link
10. Unit Price, Strip Price and Composition
Unit price: ā§ŗ7.00
Strip price: ā§ŗ70.00 (10 tablets)
Available alternative brands use the same Ornidazole 500 mg composition.
11. Mechanism of Action
Ornidazole undergoes intracellular reduction in susceptible organisms. Its reactive metabolites damage microbial DNA.
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŦāĻžāĻŖā§āϰ DNA āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻāϰ⧠āĻā§āĻŦāĻžāĻŖā§ āϧā§āĻŦāĻāϏ āĻāϰā§āĨ¤
12. Drug Indications
âĸ Bacterial vaginosisāĨ¤
âĸ TrichomoniasisāĨ¤
âĸ AmoebiasisāĨ¤
âĸ GiardiasisāĨ¤
âĸ Susceptible anaerobic bacterial infectionsāĨ¤
13. Drug Interactions and Contraindications
Interactions: Oral anticoagulants-āĻāϰ āϏāĻā§āĻā§ bleeding risk āĻŦāĻžāĻĄāĻŧāϤ⧠āĻĒāĻžāϰā§; 5-fluorouracil-āĻāϰ clearance āĻĒā§āϰāĻāĻžāĻŦāĻŋāϤ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
Contraindications: Nitroimidazole hypersensitivity āĻāĻŦāĻ MedEx āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻŋāĻā§ central/peripheral neurological disordersāĨ¤
14. Precautions and Warnings
Vertigo, ataxia, confusion, neurological symptoms, severe hepatic dysfunction āĻ āĻĨāĻŦāĻž prolonged therapy-āϤ⧠āϏāϤāϰā§āĻāϤāĻžāĨ¤
15. Dosage and Administration
MedEx-āĻāϰ examples:
Trichomoniasis: 500 mg twice daily for five days āĻ āĻĨāĻŦāĻž indication-specific alternative regimenāĨ¤
Bacterial vaginosis: MedEx-āĻāϰ Ornil monograph-āĻ 500 mg once daily for five to seven days-āϏāĻš āĻāĻŋāĻā§ regimen āĻāϞā§āϞā§āĻ āĻāĻā§āĨ¤
Prescription: 500 mg āϤāĻŋāύāĻŦāĻžāϰ āĻĻā§āύāĻŋāĻ āϞā§āĻāĻž āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§āĨ¤ āĻāĻāĻŋ āĻāĻĒāϰā§āĻā§āϤ āϏāĻžāϧāĻžāϰāĻŖ regimen āĻĨā§āĻā§ āĻāĻŋāύā§āύ; original indication āĻāĻŦāĻ frequency āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻāϰā§āϰāĻŋāĨ¤
CDC-āĻāϰ BV āĻ PID guidelines-āĻ routinely recommended antimicrobial regimens Ornidazole-āĻāĻŋāϤā§āϤāĻŋāĻ āύāϝāĻŧāĨ¤ āĻĢāϞ⧠Ornil-āĻāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰ guideline-recommended metronidazole regimen-āĻā§ āϏā§āĻŦāϝāĻŧāĻāĻā§āϰāĻŋāϝāĻŧāĻāĻžāĻŦā§ āĻāĻ āĻŦāϞ⧠āϧāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
16. Pregnancy and Lactation
Pregnancy āĻāĻŦāĻ breastfeeding-āĻ āĻĒāϰā§āϝāĻžāĻĒā§āϤ clinical safety evidence āϏā§āĻŽāĻŋāϤ; āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ indication āĻ risk assessment āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Clinical confidence: 0.98 for verified pharmacology; 0.65 for patient's indication.
Medicine 3 â Tab. Algin 50 mg
1. Generic Name
Tiemonium Methylsulfate â āĻāĻžāĻāĻŽā§āύāĻŋāϝāĻŧāĻžāĻŽ āĻŽāĻŋāĻĨāĻžāĻāϞāϏāĻžāϞāĻĢā§āĻāĨ¤
2. Brand Name
Algin 50 mg Tablet
Manufacturer: Renata PLC.
3. MedEx Alternative Brands
Aspasom, Deltimo, Dysma āĻāĻŦāĻ EmogināĨ¤
4. MedEx Therapeutic Class
Anticholinergics.
5. Pharmacological Class
Anticholinergic antispasmodic.
6. Use/Purpose
Uterine, intestinal, biliary āĻāĻŦāĻ urinary tract smooth-muscle spasm āĻāĻŽāĻžāύā§āĨ¤
7. Why Doctor Prescribed This Drug in This Patient
Likely purpose: Lower abdominal/pelvic cramping āĻāĻŽāĻžāύā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžāϝāĻŧā§ āĻŦāĻž āϤāϞāĻĒā§āĻā§āϰ āĻĒā§āĻļāĻŋāϰ āĻāĻŋāĻāĻā§āύāĻŋāĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻž āĻāĻŽāĻžāϤ⧠āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.90
8. Side Effects
Tachycardia, hypotension, dry mouth āĻ āĻĨāĻŦāĻž visual disturbance āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
9. MedEx Link
10. Unit Price, Strip Price and Composition
Unit price: ā§ŗ8.50
Strip price: ā§ŗ85.00 (10 tablets)
Other forms: syrup 10 mg/5 mL āĻāĻŦāĻ injection 5 mg/2 mLāĨ¤
11. Mechanism
Anticholinergic action-āĻāϰ āĻŽāĻžāϧā§āϝāĻŽā§ visceral smooth muscle contraction āĻāĻŽāĻžāϝāĻŧāĨ¤
12. Indications
Functional intestinal, biliary, urinary āĻāĻŦāĻ gynecological spasm-related paināĨ¤
13. Interactions and Contraindications
Other anticholinergics-āĻāϰ āϏāĻā§āĻā§ additive adverse effects āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Contraindications: Angle-closure glaucoma risk āĻāĻŦāĻ urinary retention riskāĨ¤
14. Precautions
Cardiovascular disease, renal/hepatic impairment āĻāĻŦāĻ visual disturbances-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āϏāϤāϰā§āĻāϤāĻžāĨ¤
15. Dosage and Administration
MedEx āĻ āύā§āϝāĻžāϝāĻŧā§ usual adult oral dosage 2â6 tablets daily in divided dosesāĨ¤
Prescription-āĻ āϏāĻŽā§āĻāĻŦāϤ 1+1+1 āϞā§āĻāĻž āϰāϝāĻŧā§āĻā§āĨ¤
16. Pregnancy and Lactation
Pregnancy-āϤ⧠benefitârisk review āĻāĻŦāĻ breastfeeding-āĻ āĻĒāϰā§āϝāĻžāĻĒā§āϤ safety data āύāĻž āĻĨāĻžāĻāĻžāϝāĻŧ āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Clinical confidence: 0.97
Medicine 4 â Tab. Esonix 20 mg
1. Generic Name
Esomeprazole â āĻāϏā§āĻŽāĻŋāĻĒā§āϰāĻžāĻāϞāĨ¤
2. Brand Name
Esonix 20 mg EC Tablet
Manufacturer: Incepta Pharmaceuticals Ltd.
3. MedEx Alternative Brands
Esoral, Esopra āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ Esomeprazole brandsāĨ¤
4. MedEx Therapeutic Class
Proton Pump Inhibitor.
5. Pharmacological Class
Gastric Hâē/Kâē-ATPase inhibitorāĨ¤
6. Use/Purpose
Gastric acid secretion āĻāĻŽāĻžāύā§āĨ¤
7. Why Doctor Prescribed This Drug in This Patient
Possible purpose: Gastric symptoms āĻŦāĻž acid-related discomfort controlāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻā§āϝāĻžāϏā§āĻā§āϰāĻŋāĻ āĻ ā§āϝāĻžāϏāĻŋāĻĄ āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠GERD āĻŦāĻž ulcer-āĻāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ diagnosis āϞā§āĻāĻž āύā§āĻāĨ¤
Confidence: 0.65
8. Side Effects
Headache, diarrhea, nausea, abdominal discomfort āĻāĻŦāĻ constipationāĨ¤
9. MedEx Link
10. Unit Price, Strip Price and Composition
Unit price: ā§ŗ7.00
Strip price: ā§ŗ98.00 (14 tablets)
Other forms: 40 mg tablets, 20/40 mg capsules, injection āĻāĻŦāĻ powderāĨ¤
11. Mechanism
Gastric parietal cell-āĻāϰ proton pump block āĻāϰ⧠gastric acid production āĻāĻŽāĻžāϝāĻŧāĨ¤
12. Indications
GERD, erosive esophagitis, acid-related dyspepsia, peptic ulcer disease āĻāĻŦāĻ selected H. pylori regimensāĨ¤
13. Interactions and Contraindications
Clopidogrel-āĻāϰ antiplatelet effect āĻāĻŽāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻāĻŋāĻā§ antiretroviral medicine āĻāĻŦāĻ pH-dependent absorption drugs-āĻāϰ āϏāĻā§āĻā§ interaction āĻšāϝāĻŧāĨ¤
Known hypersensitivity-āϤ⧠contraindicatedāĨ¤
14. Precautions
Long-term use-āĻ hypomagnesemia, vitamin B12 deficiency, kidney injury āĻāĻŦāĻ infection-related concerns āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
15. Dosage
āĻ āύā§āĻ GERD/acid-related indication-āĻ 20 mg once daily āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧāĨ¤
Prescription-āĻ āϏāĻŽā§āĻāĻŦāϤ 1+0+1āĨ¤ āĻāĻ twice-daily schedule-āĻāϰ indication āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻĻāϰāĻāĻžāϰāĨ¤
16. Pregnancy and Lactation
Pregnancy āĻŦāĻž breastfeeding-āĻ clinical indication āĻ āύā§āϝāĻžāϝāĻŧā§ benefitârisk assessment āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Clinical confidence: 0.98 for pharmacology; 0.65 for patient-specific rationale.
Medicine 5 â Tab. Thyrox 50 mcg
1. Generic Name
Levothyroxine Sodium â āϞāĻŋāĻā§āĻĨāĻžāĻāϰāĻā§āϏāĻŋāύ āϏā§āĻĄāĻŋāϝāĻŧāĻžāĻŽāĨ¤
2. Brand Name
Thyrox 50 mcg Tablet
Manufacturer: Renata PLC.
3. MedEx Alternative Brands
Euthycin, Euthyrox, Leroid āĻāĻŦāĻ ThyronorāĨ¤
4. MedEx Therapeutic Class
Thyroid Hormones.
5. Pharmacological Class
Synthetic thyroid hormone T4 replacementāĨ¤
6. Use/Purpose
Hypothyroidism treatmentāĨ¤
7. Why Doctor Prescribed This Drug in This Patient
Possible history of subclinical āĻŦāĻž established hypothyroidismāĨ¤
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻĨāĻžāĻāϰāϝāĻŧā§āĻĄ āĻšāϰāĻŽā§āύā§āϰ āĻāĻžāĻāϤāĻŋ āĻĨāĻžāĻāϞ⧠āϤāĻž āĻĒā§āϰāĻŖā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ TSH āĻāĻŦāĻ FT4 āϰāĻŋāĻĒā§āϰā§āĻ āύāĻž āĻĨāĻžāĻāĻžāϝāĻŧ SCH āύāĻŋāĻļā§āĻāĻŋāϤ āύāϝāĻŧāĨ¤
Confidence: 0.70
8. Side Effects
Excessive dose-āĻ palpitations, tachycardia, tremor, sweating, anxiety āĻāĻŦāĻ insomniaāĨ¤
9. MedEx Link
10. Unit Price, Strip Price and Other Composition
Unit price: ā§ŗ2.20
30 tablets-āĻāϰ āĻŽā§āϞā§āϝ: ā§ŗ66.00
90-tablet pack: ā§ŗ198.00
Other strengths: 25, 75 āĻāĻŦāĻ 100 mcg tabletsāĨ¤
11. Mechanism
Levothyroxine synthetic T4 āĻšāĻŋāϏā§āĻŦā§ āĻāĻžāĻ āĻāϰā§āĨ¤ Peripheral tissues-āĻ āĻāĻŋāĻā§ T4, active T3-āϤ⧠convert āĻšāϝāĻŧāĨ¤
12. Indications
Primary hypothyroidism, selected secondary hypothyroidism āĻāĻŦāĻ āĻāĻŋāĻā§ thyroid-related suppression indicationsāĨ¤
13. Interactions and Contraindications
Calcium, iron, antacids āĻāĻŦāĻ āĻāĻŋāĻā§ acid-suppressing medicines levothyroxine absorption āĻĒā§āϰāĻāĻžāĻŦāĻŋāϤ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
Contraindications: Untreated thyrotoxicosis āĻāĻŦāĻ uncorrected adrenal insufficiencyāĨ¤
14. Precautions
Cardiac disease, arrhythmia, pregnancy āĻāĻŦāĻ dose changes-āĻāϰ āϏāĻŽāϝāĻŧ TSH/FT4 monitoring āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
15. Dosage and Administration
Prescription-āĻ āϏāĻŽā§āĻāĻŦāϤ 50 mcg once dailyāĨ¤
āϏāĻžāϧāĻžāϰāĻŖāϤ āϏāĻāĻžāϞ⧠āĻāĻžāϞāĻŋ āĻĒā§āĻā§ āĻāĻžāĻŦāĻžāϰā§āϰ 30â60 āĻŽāĻŋāύāĻŋāĻ āĻāĻā§ āύā§āĻāϝāĻŧāĻž āĻšāϝāĻŧāĨ¤ Iron/calcium āĻĨā§āĻā§ āĻ āύā§āϤāϤ āĻāĻžāϰ āĻāĻŖā§āĻāĻžāϰ āĻŦā§āϝāĻŦāϧāĻžāύ āϰāĻžāĻāĻž āĻāĻāĻŋāϤāĨ¤
Dose TSH āĻāĻŦāĻ FT4 āĻ āύā§āϝāĻžāϝāĻŧā§ āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āĻšāϝāĻŧāĨ¤
16. Pregnancy and Lactation
Hypothyroidism āĻĨāĻžāĻāϞ⧠pregnancy-āϤ⧠levothyroxine treatment āĻŦāĻŋāĻļā§āώāĻāĻžāĻŦā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤ Breastfeeding-āĻ āϏāĻžāϧāĻžāϰāĻŖ replacement therapy compatibleāĨ¤
Clinical confidence: 0.99 for drug information; 0.70 for patient's thyroid diagnosis.
Medicine 6 â Tab. Folix 5 mg
1. Generic Name
Folinic Acid â āĻĢāϞāĻŋāύāĻŋāĻ āĻ ā§āϝāĻžāϏāĻŋāĻĄāĨ¤
Also known as Calcium Folinate / LeucovorināĨ¤
Important: Folix 5 mg is NOT ordinary Folic Acid 5 mg.
2. Brand Name
Folix 5 mg Tablet
Manufacturer: ACME Laboratories Ltd.
3. MedEx Alternative Brands
Actifol, Biofol, Folidel, Folimax, Folinic āĻāĻŦāĻ FolitaāĨ¤
4. MedEx Therapeutic Class
Supportive Care Therapy.
5. Pharmacological Class
Reduced folate derivative / Folate rescue agent.
6. Use/Purpose
Folate-antagonist toxicity management, selected megaloblastic anemia āĻāĻŦāĻ certain oncology protocolsāĨ¤
7. Why Doctor Prescribed This Drug in This Patient
Possible purpose: Folate-related deficiency āĻŦāĻž hematological supportāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻā§āύ⧠folate-related deficiency āĻŦāĻž anemia-related indication āĻĨāĻžāĻāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰ⧠āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
āĻāĻŋāύā§āϤ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠anemia diagnosis, CBC, vitamin B12 āĻŦāĻž folate assay āύā§āĻāĨ¤
āϤāĻžāĻ āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠Folix āĻĻā§āĻāϝāĻŧāĻžāϰ āϏā§āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖ āĻĒā§āϰāϤāĻŋāώā§āĻ āĻŋāϤ āύāϝāĻŧāĨ¤
Patient-specific rationale confidence: 0.45
8. Side Effects
Hypersensitivity āĻāĻŦāĻ gastrointestinal effects āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ Chemotherapy-associated regimens-āĻ mucositis, stomatitis, diarrhea āĻ hematological adverse events āĻĻā§āĻāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§, āϤāĻŦā§ āϏāĻŦāĻā§āϞā§āĻā§ low-dose Folix-āĻāϰ āύāĻŋāĻāϏā§āĻŦ āĻĒā§āϰāĻāĻžāĻŦ āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
9. MedEx Link
10. Unit Price, Strip Price and Other Composition
Unit price: ā§ŗ9.00
Strip price: ā§ŗ90.00 (10 tablets)
Also available as Folix 15 mg tabletāĨ¤
11. Mechanism of Action
Folinic acid āĻšāϞ⧠biologically active reduced folate derivativeāĨ¤ āĻāĻāĻŋ purine āĻāĻŦāĻ thymidylate synthesis-āĻ āϏāĻšāĻžāϝāĻŧāϤāĻž āĻāϰ⧠āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ folate-antagonist toxicity-āϤ⧠normal cells rescue āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
12. Drug Indications
âĸ Methotrexate rescueāĨ¤
âĸ Selected folate-antagonist toxicityāĨ¤
âĸ Folate-responsive megaloblastic anemiaāĨ¤
âĸ Specific chemotherapy regimensāĨ¤
13. Drug Interactions and Contraindications
Interactions: Phenytoin, phenobarbital, primidone āĻāĻŦāĻ fluoropyrimidines-āĻāϰ āϏāĻā§āĻā§ clinically important interactions āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Contraindications: Hypersensitivity; untreated vitamin B12 deficiency-related pernicious anemia-āϤ⧠folinic acid āĻāĻāĻž āϝāĻĨāĻžāϝāĻĨ treatment āύāϝāĻŧāĨ¤
14. Precautions and Warnings
Methotrexate āĻŦāĻž chemotherapy-associated āĻŦā§āϝāĻŦāĻšāĻžāϰ specialist-supervised āĻšāϤ⧠āĻšāĻŦā§āĨ¤ Vitamin B12 deficiency āĻŦāĻžāĻĻ āĻĻā§āĻāϝāĻŧāĻž āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
15. Dosage and Administration
MedEx-āĻ folate-deficiency-associated megaloblastic anemia-āϰ āĻāύā§āϝ 5â15 mg/day āĻāϞā§āϞā§āĻ āϰāϝāĻŧā§āĻā§āĨ¤ āĻ āύā§āϝ indications-āĻ dose āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻāϞāĻžāĻĻāĻžāĨ¤
Prescription-āĻ āϏāĻŽā§āĻāĻŦāϤ 0+1+0āĨ¤
16. Pregnancy and Lactation
Pregnancy āĻāĻŦāĻ lactation-āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ indication āĻ āύā§āϝāĻžāϝāĻŧā§ benefitârisk assessment āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Clinical confidence: 0.99 for generic identity and pharmacology; 0.45 for patient-specific indication.
𩷠8. Bangladesh Clinical Practice â Cervical Erosion and Associated Disorders Medicines Used by Doctors
āĻāĻ āĻ āĻāĻļāĻāĻŋ Bangladesh drug formulary āĻ guideline-based comparisonāĨ¤ āϏāĻŦāĻā§āϞ⧠āĻāώā§āϧ cervical erosion-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āύāϝāĻŧāĨ¤ āϝ⧠āϰā§āĻ āĻŦāĻž āĻāĻāĻŋāϞāϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāĻŦā§, āĻļā§āϧ⧠āϏā§āĻ indication āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāĻž āĻšāĻŦā§āĨ¤
Table 1 â Bangladesh Clinical Drug Comparison
| Generic | Example Brand | MedEx Therapeutic Class | Relevant Condition | Indicative Price |
|---|---|---|---|---|
| Flucloxacillin | Fluclox 500 | Narrow Spectrum Penicillin | Susceptible Gram-positive infection | ā§ŗ14/capsule |
| Ornidazole | Ornil 500 | Amoebicides, Anti-diarrhoeal Antiprotozoal | Selected anaerobic/protozoal infection | ā§ŗ7/tablet |
| Tiemonium Methylsulfate | Algin 50 | Anticholinergics | Pelvic spasm | ā§ŗ8.50/tablet |
| Paracetamol | Napa 500 | Non-opioid analgesic/antipyretic | Postprocedural pain | ā§ŗ1.20/tablet |
| Metronidazole | Metryl 500 | Amoebicides, Anti-diarrhoeal Antiprotozoal | BV; part of PID regimens | ā§ŗ2/tablet |
| Doxycycline | Doxicap 100 | Tetracycline antibiotic | Selected cervicitis/PID regimens | ā§ŗ2.20/capsule |
| Ceftriaxone | Ceftron 500 mg IM | Third-generation cephalosporin | Gonorrhea/PID regimen component | ā§ŗ200/vial |
| Clindamycin vaginal cream | Clindacin 2% | Lincosamide antibiotic | BV alternative | ā§ŗ70/20 g tube |
| Esomeprazole | Esonix 20 | Proton Pump Inhibitor | Acid-related disorders | ā§ŗ7/tablet |
| Levothyroxine | Thyrox 50 mcg | Thyroid Hormones | Confirmed hypothyroidism | ā§ŗ2.20/tablet |
| Folinic Acid | Folix 5 | Supportive Care Therapy | Selected folate-related indications | ā§ŗ9/tablet |
Prices: MedEx-listed reference prices, not guaranteed current pharmacy selling prices.
Table 2 â Condition-Specific Evidence-Based Treatment Comparison
| Confirmed Clinical Condition | Guideline-Based Approach | Why Used | Important Restriction |
|---|---|---|---|
| Uncomplicated cervical ectropion | Observation if asymptomatic | Benign condition | Routine antibiotics not indicated |
| Symptomatic persistent ectropion | Specialist assessment; selected cautery/cryotherapy | Treat troublesome symptoms | Exclude infection and abnormal cervical pathology |
| Bacterial vaginosis | Metronidazole or intravaginal clindamycin | Treat vaginal anaerobic dysbiosis | Diagnosis needed |
| Trichomoniasis | Appropriate nitroimidazole regimen | Eradicate T. vaginalis | Partner treatment is important |
| Suspected PID | Ceftriaxone + doxycycline + metronidazole, when outpatient regimen appropriate | Broad coverage | This is a combination regimen, not interchangeable individual options |
| Postprocedural infection | Clinical assessment and infection-specific treatment | Control infection | Severe cases may require admission/IV antibiotics |
| Hypothyroidism | Levothyroxine | Hormone replacement | TSH/FT4 monitoring |
| Confirmed folate-related anemia | Appropriate folate therapy | Correct deficiency | Verify B12 status and exact indication |
Confidence: 0.97 for guideline-based management principles.
Drug-Specific Bangladesh Clinical Practice Notes
1. Paracetamol â Napa 500 mg:
Generic: Paracetamol. āĻŦā§āϝāĻŦāĻšāĻžāϰ: postoperative pain/feverāĨ¤ MedEx price ā§ŗ1.20/unit; ā§ŗ12/stripāĨ¤ āϝāĻā§āϤā§āϰ āϰā§āĻ, combination medicines āĻ total daily dose āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāϝāĻŧāĨ¤ MedExâNapa
2. Metronidazole â Metryl 500 mg:
Generic: Metronidazole. āĻŦā§āϝāĻŦāĻšāĻžāϰ: symptomatic BV āĻ āĻĨāĻŦāĻž broader PID regimen-āĻāϰ āĻ āĻāĻļāĨ¤ MedEx-listed price ā§ŗ2/unitāĨ¤ Pregnancy, interactions āĻāĻŦāĻ treatment indication āĻ āύā§āϝāĻžāϝāĻŧā§ regimen āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ MedExâMetronidazole Brands
3. Doxycycline â Doxicap 100 mg:
Generic: Doxycycline Hydrochloride. āĻŦā§āϝāĻŦāĻšāĻžāϰ: selected cervicitis āĻāĻŦāĻ PID regimensāĨ¤ Price ā§ŗ2.20/capsule, ā§ŗ22/stripāĨ¤ Pregnancy-āϤ⧠āϏāĻžāϧāĻžāϰāĻŖāϤ avoid āĻāϰāĻž āĻšāϝāĻŧ; indication āĻ āύā§āϝāĻžāϝāĻŧā§ āĻŦāĻŋāĻāϞā§āĻĒ āϞāĻžāĻā§āĨ¤ MedExâDoxicap
4. Ceftriaxone â Ceftron 500 mg IM:
Generic: Ceftriaxone Sodium. āĻŦā§āϝāĻŦāĻšāĻžāϰ: gonococcal infection āĻāĻŦāĻ guideline-based PID treatment-āĻāϰ injectable componentāĨ¤ Price ā§ŗ200/vialāĨ¤ Penicillin/cephalosporin allergy āĻāĻŦāĻ weight/indication āĻ āύā§āϝāĻžāϝāĻŧā§ regimen āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāϝāĻŧāĨ¤ MedExâCeftriaxone Brands
5. Clindamycin vaginal cream â Clindacin 2%:
Generic: Clindamycin. āĻŦā§āϝāĻŦāĻšāĻžāϰ: symptomatic bacterial vaginosis-āĻāϰ local treatment optionāĨ¤ MedEx price ā§ŗ70/20 g tubeāĨ¤ Product-specific directions āĻ latex barrier contraception āϏāĻŽā§āĻĒāϰā§āĻā§ āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ MedExâClindamycin Vaginal Cream
đ¨ 9. My Clinical Working Assessment
đĒ 9.1 Prescription-Ready Provisional Diagnosis
Postprocedural pelvic/lower abdominal pain with mild vaginal bleeding, approximately seven days following gynecological treatment documented for cervical erosion; rule out postprocedural infection or other complications. Associated history suggestive of treated subclinical hypothyroidism.
āĻŦāĻžāĻāϞāĻž Diagnosis
āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻāϰā§āĻļāύā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āϤāϞāĻĒā§āĻā§āϰ āĻŦā§āϝāĻĨāĻž āĻ āϏāĻžāĻŽāĻžāύā§āϝ āϝā§āύāĻŋāĻĒāĻĨā§ āϰāĻā§āϤāĻĒāĻžāϤ; āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ āĻāĻāĻŋāϞāϤāĻž āĻŦāĻžāĻĻ āĻĻā§āĻāϝāĻŧāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ āϏāĻā§āĻā§ āĻāĻŋāĻāĻŋā§āϏāĻžāϧā§āύ āϏāĻžāĻŦāĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻšāĻžāĻāĻĒā§āĻĨāĻžāĻāϰāϝāĻŧā§āĻĄāĻŋāĻāĻŽā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Confidence: 0.84
đĒ 9.2 Specific Specialist Department / Doctor Referral
Primary referral: Consultant Obstetrician and Gynaecologist.
āĻŦāĻžāĻāϞāĻž: āϏā§āϤā§āϰā§āϰā§āĻ āĻ āĻĒā§āϰāϏā§āϤāĻŋāĻŦāĻŋāĻĻā§āϝāĻž āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
Reason: Postprocedural pelvic pain, vaginal bleeding āĻāĻŦāĻ cervical condition āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžāϝāĻŧāύāĨ¤
Secondary referral: Endocrinologist, āϝāĻĻāĻŋ thyroid-function results abnormal āĻšāϝāĻŧ āĻ āĻĨāĻŦāĻž thyroid treatment adjustment āĻāĻāĻŋāϞ āĻšāϝāĻŧāĨ¤
Confidence: 0.98
đ§ 9.3 Clinical Diagnosis â Disease Severity / Category / Complications
Disease category: Postprocedural gynecological symptoms following treatment for documented cervical erosionāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āϏā§āϤā§āϰā§āϰā§āĻāĻāύāĻŋāϤ āĻāĻĒāϏāϰā§āĻāĨ¤
Severity: Undetermined â āĻāĻžāϰāĻŖ pain score, current bleeding volume, temperature āĻāĻŦāĻ pelvic examination findings āύā§āĻāĨ¤
Possible complications: Postprocedural endometritis, cervicitis, persistent cervical bleeding āĻ āĻĨāĻŦāĻž āĻ āύā§āϝ uterine pathologyāĨ¤ āĻāĻā§āϞ⧠differential diagnoses, confirmed complications āύāϝāĻŧāĨ¤
Confidence: 0.90 for the need to assess; insufficient data to assign complication probabilities.
10. Differential Diagnosis â āĻŦāĻŋāĻāϞā§āĻĒ āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ
| Differential Diagnosis | āĻŦāĻžāĻāϞāĻž | Evidence Supporting Consideration | Confidence |
|---|---|---|---|
| Expected postoperative recovery | āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āϏā§āϰ⧠āĻāĻ āĻžāϰ āĻĒā§āϰāĻā§āϰāĻŋāϝāĻŧāĻž | Mild bleeding and pain after procedure | 0.85 |
| Postprocedural endometritis | āĻāϰāĻžāϝāĻŧā§āϰ āĻā§āϤāϰā§āϰ āϏā§āϤāϰ⧠āϏāĻāĻā§āϰāĻŽāĻŖ | Pain after uterine instrumentation | 0.65 |
| Cervicitis | āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš | Cervical history and bleeding | 0.65 |
| Persistent ectropion-related bleeding | āĻāĻāĻā§āϰā§āĻĒāĻŋāϝāĻŧāύāĻāύāĻŋāϤ āϰāĻā§āϤāĻĒāĻžāϤ | Documented cervical erosion history | 0.75 |
| Pregnancy-related bleeding | āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻžāĻāύāĻŋāϤ āϰāĻā§āϤāĻĒāĻžāϤ | Reproductive-age patient; pregnancy status undocumented | 0.50 |
| Retained intrauterine tissue | āĻāϰāĻžāϝāĻŧā§āϰ āĻā§āϤāϰ⧠tissue āĻĨā§āĻā§ āϝāĻžāĻāϝāĻŧāĻž | Relevant only if D&C and its indication are confirmed | 0.45 |
These confidence scores reflect diagnostic plausibility, not calculated disease probabilities.
11. Investigations â āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ āĻĒāϰā§āĻā§āώāĻž
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻā§āĻā§ āĻā§āύ⧠laboratory āĻŦāĻž imaging report āϏāĻāϝā§āĻā§āϤ āύā§āĻāĨ¤
| Investigation | Purpose | āĻŦāĻžāĻāϞāĻž |
|---|---|---|
| CBC | Evaluate anemia or infection-associated changes | āϰāĻā§āϤāϏā§āĻŦāϞā§āĻĒāϤāĻž āĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ |
| Urine/serum β-hCG | Exclude pregnancy-related causes when applicable | āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž-āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻāĻžāϰāĻŖ āĻŦāĻžāĻĻ āĻĻā§āĻāϝāĻŧāĻž |
| Speculum examination | Assess cervix and bleeding source | āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻ āĻ āϰāĻā§āϤāĻĒāĻžāϤā§āϰ āĻā§āϏ āĻĻā§āĻāĻž |
| Bimanual pelvic examination | Assess uterine/adnexal tenderness | āĻāϰāĻžāϝāĻŧā§ āĻ āĻāĻļāĻĒāĻžāĻļā§āϰ āĻ āĻāĻļā§ āĻŦā§āϝāĻĨāĻž āĻāĻā§ āĻāĻŋ āύāĻž āĻĻā§āĻāĻž |
| Pelvic USG/TVS | Evaluate uterine cavity if indicated | āĻāϰāĻžāϝāĻŧā§āϰ āĻā§āϤāϰā§āϰ āĻ āĻŦāϏā§āĻĨāĻž āĻĻā§āĻāĻž |
| Infection testing | Identify suspected cervicitis/STI/vaginal infection | āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻā§āĻŦāĻžāĻŖā§ āĻļāύāĻžāĻā§āϤ |
| TSH, FT4 | Confirm thyroid status | āĻĨāĻžāĻāϰāϝāĻŧā§āĻĄā§āϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž |
| Vitamin B12/folate tests | If anemia or deficiency is suspected | āĻāĻŋāĻāĻžāĻŽāĻŋāύā§āϰ āĻāĻžāĻāϤāĻŋ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ |
| Cervical screening | Age- and history-appropriate screening | āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ precancerous āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻļāύāĻžāĻā§āϤ |
Confidence: 0.96 for the investigation framework.
12. Etiology and Pathophysiology â āϰā§āĻā§āϰ āĻāĻžāϰāĻŖ āĻ āĻĒā§āϰāĻā§āϰāĻŋāϝāĻŧāĻž
Cervical ectropion
Estrogen-related epithelial changes-āĻāϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻāĻāĻŋ āϏāĻžāϧāĻžāϰāĻŖāϤ benignāĨ¤
Confidence: 0.98
Postprocedural pain and bleeding
Cervical or uterine instrumentation-āĻāϰ āĻĒāϰ⧠temporary tissue irritation, healing-related spotting āĻ āĻĨāĻŦāĻž cramping āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.95
Possible infection
Infection āĻšāϞ⧠uterine/cervical inflammation, pelvic pain, fever āĻŦāĻž abnormal discharge āĻĻā§āĻāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ āĻļā§āϧ⧠antibiotic prescription āĻĨāĻžāĻāĻžāϰ āĻāĻžāϰāĻŖā§ infection confirmed āĻŦāϞāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤
Confidence: 0.97
Subclinical hypothyroidism
TSH āĻŦā§āĻļāĻŋ āĻāĻŦāĻ FT4 āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĨāĻžāĻāϞ⧠biochemical diagnosis āĻāϰāĻž āĻšāϝāĻŧāĨ¤ āϰā§āĻā§āϰ āĻā§āύ⧠thyroid report āύāĻž āĻĨāĻžāĻāĻžāϝāĻŧ diagnosis āϝāĻžāĻāĻžāĻāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤
Confidence: 0.99 for definition; 0.70 for patient-specific possibility.
13. Management and Treatment â Guideline-Based Review
A. Cervical erosion/ectropion
Asymptomatic ectropion-āĻ observation āϝāĻĨā§āώā§āĻ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ Persistent troublesome bleeding āĻŦāĻž discharge āĻĨāĻžāĻāϞ⧠clinician assessment-āĻāϰ āĻĒāϰ⧠selected local treatment āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻšāϝāĻŧāĨ¤
B. Postprocedural pain
āĻŦā§āϝāĻĨāĻž mild āĻ improving āĻšāϞ⧠observation āĻāĻŦāĻ appropriate analgesia āϝāĻĨā§āώā§āĻ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ worsening pain, fever āĻ āĻĨāĻŦāĻž heavy bleeding āĻĨāĻžāĻāϞ⧠urgent assessment āĻāϰā§āϰāĻŋāĨ¤
C. Antibiotic appropriateness
Fluclox + Ornil combination āĻāĻā§ āϏāϰāĻžāϏāϰāĻŋ guideline-standard PID regimen āĻŦāϞāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤
PID āϏāύā§āĻĻā§āĻš āĻšāϞ⧠CDC-recommended treatment-āĻ āϏāĻžāϧāĻžāϰāĻŖāϤ ceftriaxone, doxycycline āĻ metronidazole-āĻāĻŋāϤā§āϤāĻŋāĻ regimen āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧāĨ¤ Confirmed postoperative infection-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϧāϰāύ āĻ severity āĻ āύā§āϝāĻžāϝāĻŧā§ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻšāϝāĻŧāĨ¤
D. Hypothyroidism
NICE NG145 āĻ āύā§āϝāĻžāϝāĻŧā§ subclinical hypothyroidism-āĻ levothyroxine treatment decision TSH level, repeated measurements, symptoms āĻāĻŦāĻ clinical circumstances-āĻāϰ āĻāĻĒāϰ āύāĻŋāϰā§āĻāϰ āĻāϰā§āĨ¤
E. Folix
Folinic acid-āĻāϰ āĻāύā§āϝ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ indication āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ Cervical ectropion-āĻāϰ routine treatment āĻšāĻŋāϏā§āĻŦā§ āĻāĻāĻŋ āĻĒā§āϰāϤāĻŋāώā§āĻ āĻŋāϤ āύāϝāĻŧāĨ¤
Overall management review confidence: 0.96.
14. đŠ Doctor's Diagnosis vs My Diagnosis â Areas of Agreement
âĸ Doctor: History of cervical erosionāĨ¤ My assessment: Documented cervical condition; ectropion āĻāĻāĻāĻŋ āϏāĻŽā§āĻāĻžāĻŦā§āϝ clinical interpretationāĨ¤ Agreement confidence: 0.94.
âĸ Doctor: Seven-day postoperative follow-upāĨ¤ My assessment: Postprocedural clinical stateāĨ¤ Agreement confidence: 0.95.
âĸ Doctor: Pelvic pain and mild vaginal bleedingāĨ¤ My assessment: Same presenting symptoms with complication assessmentāĨ¤ Agreement confidence: 0.96.
âĸ Doctor: Possible SCH and Thyrox treatmentāĨ¤ My assessment: Possible thyroid disorder requiring biochemical confirmationāĨ¤ Agreement confidence: 0.75.
Agreement Conclusion
Doctor's documented diagnosis and my clinical working assessment are broadly similar.
āϤāĻŦā§ āĻāĻŽāĻžāϰ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύāĻāĻŋ symptom-based differential diagnosis āĻ medication audit-āĻāϰ āĻāĻžāϰāĻŖā§ āĻāĻŋāĻā§āĻāĻž āĻŦāĻŋāϏā§āϤā§āϤāĨ¤
15. đ§ Doctor's Diagnosis vs My Diagnosis â Areas of Difference
Difference 1 â Procedure identification
Doctor's note: D&C and another cervical procedure may have been documented.
My assessment: Exact operative procedure cannot be confirmed from the handwriting alone.
Important: D&C is not a routine treatment for uncomplicated cervical ectropion. āϝāĻĻāĻŋ āϏāϤā§āϝāĻŋāĻ D&C āĻšāϝāĻŧā§ āĻĨāĻžāĻā§, āϤāĻžāĻšāϞ⧠āĻāϰ āĻāϞāĻžāĻĻāĻž uterine indication āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤ Operation note āϝāĻžāĻāĻžāĻ āĻāϰā§āϰāĻŋāĨ¤
Confidence: 0.95
Difference 2 â Infection diagnosis
Doctor's prescription: Fluclox and Ornil.
My assessment: These medicines suggest that infection coverage may have been considered, but infection is not proven.
Confidence: 0.98
Difference 3 â Thyroid diagnosis
Doctor's note: Possible SCH.
My assessment: TSH āĻāĻŦāĻ FT4 āĻāĻžāĻĄāĻŧāĻž SCH āĻŦāύāĻžāĻŽ overt hypothyroidism āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.99
Difference 4 â Folix indication
Doctor prescribed: Folix 5 mg.
My assessment: Specific anemia, folate deficiency āĻ āĻĨāĻŦāĻž folate-antagonist indication āύā§āĻāĨ¤
Confidence: 0.99 for lack of documented indication.
Final Comparison Conclusion
The physician's documented clinical impression and the independent working diagnosis are substantially consistent, but the evidence is insufficient to confirm postoperative infection, exact procedure type or thyroid disease category.
16. Clinical Prescription Demo â Prescription-Ready Documentation
LIPU MED â Educational Clinical Note
Patient: Female, approximately 39 years
Visit: Gynecological postoperative follow-up
History: Cervical erosion; seven days after reported procedure
C/C: Pelvic pain and mild vaginal bleeding
Provisional Diagnosis
Postprocedural pelvic pain with mild vaginal bleeding following gynecological treatment for cervical erosion; rule out postoperative infection and other complications. Possible history of subclinical hypothyroidism.
āĻŦāĻžāĻāϞāĻž Dx
āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻāϰā§āĻļāύā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āϤāϞāĻĒā§āĻā§āϰ āĻŦā§āϝāĻĨāĻž āĻ āĻ āϞā§āĻĒ āϰāĻā§āϤāĻĒāĻžāϤ; āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāĻāĻŋāϞāϤāĻž āĻŦāĻžāĻĻ āĻĻāĻŋāϤ⧠āĻšāĻŦā§āĨ¤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻžāĻŦāĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻšāĻžāĻāĻĒā§āĻĨāĻžāĻāϰāϝāĻŧā§āĻĄāĻŋāĻāĻŽā§āϰ āĻĒā§āϰā§āĻŦāĻāϤāĻŋāĻšāĻžāϏāĨ¤
Rx â Original Prescription Record
| Medicine | Original Apparent Schedule | Verification Required |
|---|---|---|
| Fluclox 500 mg | 1+1+1 | Confirm exact duration and indication |
| Ornil 500 mg | 1+1+1 | Confirm frequency and indication |
| Algin 50 mg | 1+1+1 | Confirm duration |
| Esonix 20 mg | 1+0+1 | Confirm indication and duration |
| Thyrox 50 mcg | 1+0+0 | Review TSH/FT4 and previous dose |
| Folix 5 mg | 0+1+0 | Confirm indication and duration |
āĻāĻ āĻā§āĻŦāĻŋāϞāĻāĻŋ original prescription transcription, āύāϤā§āύ prescription āύāϝāĻŧāĨ¤
Investigation Plan
Clinical examination-āĻāϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠CBC, pregnancy test, pelvic examination, TVS, infection testing āĻ thyroid function testing āύāĻŋāϰā§āĻŦāĻžāĻāύāĨ¤
Advice
Heavy vaginal bleeding, increasing pelvic pain, fever, fainting āĻŦāĻž foul-smelling discharge āĻšāϞ⧠urgent gynecological assessmentāĨ¤
Specialist Referral
Consultant Obstetrician and Gynaecologist.
Thyroid abnormality āĻĨāĻžāĻāϞ⧠Endocrinology reviewāĨ¤
Clinical documentation confidence: 0.96.
17. Overview / Summary, Actionable Plan and References
A. Overview / Summary
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ corrected clinical review āĻĨā§āĻā§ āĻŦā§āĻāĻž āϝāĻžāĻā§āĻā§, āϰā§āĻā§ cervical erosion-āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĒāϰ⧠pelvic pain āĻ mild vaginal bleeding āύāĻŋāϝāĻŧā§ āĻĢāϞā§āĻāĻĒā§ āĻāϏā§āĻā§āύāĨ¤
āĻāϝāĻŧāĻāĻŋ āĻāώā§āϧā§āϰ generic āĻāĻāύ MedEx āĻ āύā§āϝāĻžāϝāĻŧā§ āĻļāύāĻžāĻā§āϤ āĻšāϝāĻŧā§āĻā§āĨ¤
Fluclox āĻāĻāĻāĻŋ penicillin antibioticāĨ¤
Ornil āĻāĻāĻāĻŋ nitroimidazole antimicrobialāĨ¤
Algin antispasmodicāĨ¤
Esonix gastric acid suppressantāĨ¤
Thyrox thyroid hormone replacementāĨ¤
Folix folinic acid preparationāĨ¤
āϤāĻŦā§ medication indication āĻāĻŦāĻ āϰā§āĻā§āϰ definitive diagnosis-āĻāϰ āĻŽāϧā§āϝ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ evidence gaps āϰāϝāĻŧā§āĻā§āĨ¤
Overall confidence: 0.84
B. Actionable Plan
Step 1: Original operation note āϏāĻāĻā§āϰāĻš āĻāϰ⧠exact procedure āĻ indication āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 2: Original prescription-āĻāϰ Fluclox āĻ Ornil-āĻāϰ dosing schedule āĻāĻŦāĻ duration āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 3: Postprocedural complication-āĻāϰ āĻā§āύ⧠history āĻŦāĻž symptoms āĻĨāĻžāĻāϞ⧠pelvic examination āĻāĻŦāĻ clinically indicated investigations āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 4: Thyrox indication āϝāĻžāĻāĻžāĻāϝāĻŧā§āϰ āĻāύā§āϝ TSH/FT4 āĻāĻŦāĻ previous thyroid records āĻĻā§āĻāϤ⧠āĻšāĻŦā§āĨ¤
Step 5: Folix 5 mg āĻā§āύ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§ āϤāĻž āĻāĻžāύāϤ⧠CBC, B12/folate status āĻāĻŦāĻ prior clinical history review āĻāϰāϤ⧠āĻšāĻŦā§, āϝāĻĻāĻŋ clinically indicated āĻšāϝāĻŧāĨ¤
Step 6: Cervical screening history, HPV vaccination record āĻāĻŦāĻ follow-up status āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
C. References â Textbooks, Guidelines and Peer-Reviewed Journals
Standard Textbooks
1. Williams Gynecology, 4th edition. McGraw Hill. Relevant sections on benign cervical disorders, pelvic examination and gynecological proceduresāĨ¤
2. Dutta's Textbook of Gynecology. Relevant chapters on cervical pathology and operative gynecologyāĨ¤
3. Harrison's Principles of Internal Medicine. Relevant chapters on hypothyroidism and thyroid-function abnormalitiesāĨ¤
4. Katzung's Basic & Clinical Pharmacology. Relevant chapters on beta-lactam antibiotics, antiprotozoal agents, acid-suppressing drugs and thyroid hormonesāĨ¤
5. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Relevant sections on antimicrobial pharmacology, folate metabolism and endocrine therapeuticsāĨ¤
Clinical Guidelines
1. NICE Guideline NG145 â Thyroid Disease: Assessment and Management. Original publication 2019; subsequently updated.
2. CDC Sexually Transmitted Infections Treatment Guidelines, 2021. Relevant sections on BV, cervicitis and PIDāĨ¤
3. ASCCP Risk-Based Management Guidelines, 2019, with updates through 2023. Relevant when cervical screening abnormalities are identifiedāĨ¤
Journal Articles with DOI
1. Jonklaas J, et al. Guidelines for the Treatment of Hypothyroidism. Thyroid. 2014;24(12):1670â1751.
DOI: 10.1089/thy.2014.0028āĨ¤
2. Perkins RB, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2):102â131.
DOI: 10.1097/LGT.0000000000000525āĨ¤
3. Perkins RB, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023. J Low Genit Tract Dis. 2024;28(1):3â6.
DOI: 10.1097/LGT.0000000000000788āĨ¤
Author: Md.Rafiqul Islam Lipu
Date: Friday, 16 October 2026
Time checked: 08:51 AM, Bangladesh Standard Time (UTC+06:00)
Publication: LIPU MED â Clinical Prescription Review
Final Working Diagnosis
English: Postprocedural pelvic pain with mild vaginal bleeding following gynecological treatment for documented cervical erosion; postoperative complications to be excluded. Possible history of treated subclinical hypothyroidism.
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžāϝāĻŧā§āĻŽā§āĻā§āϰ āĻāϰā§āĻļāύā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āϤāϞāĻĒā§āĻā§āϰ āĻŦā§āϝāĻĨāĻž āĻ āϏāĻžāĻŽāĻžāύā§āϝ āϝā§āύāĻŋāĻĒāĻĨā§ āϰāĻā§āϤāĻĒāĻžāϤāĨ¤ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āĻāĻāĻŋāϞāϤāĻž āĻŦāĻžāĻĻ āĻĻā§āĻāϝāĻŧāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ āϏāĻā§āĻā§ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻŋāĻāĻŋā§āϏāĻžāϧā§āύ āϏāĻžāĻŦāĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻšāĻžāĻāĻĒā§āĻĨāĻžāĻāϰāϝāĻŧā§āĻĄāĻŋāĻāĻŽā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Final diagnostic confidence: 0.84/1.00.
Clinical verification status: āĻāϝāĻŧāĻāĻŋ āĻāώā§āϧā§āϰ āύāĻžāĻŽ āϏāĻāĻļā§āϧāĻŋāϤ āĻ MedEx-āĻ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤ āϤāĻŦā§ operation note, laboratory reports, examination findings āĻāĻŦāĻ āĻāĻŋāĻā§ handwritten dose/duration āĻ āϏā§āĻĒāώā§āĻ āĻĨāĻžāĻāĻžāϝāĻŧ āĻāĻāĻŋāĻā§ definitive confirmed diagnosis āĻŦāĻž āύāϤā§āύ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āĻĻā§āĻļ āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤